FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1910228005> ?p ?o ?g. }

• W1910228005 endingPage "944" @default.
• W1910228005 startingPage "937" @default.
• W1910228005 abstract "PURPOSE To determine the maximum-tolerated dose (MTD) of cyclophosphamide (CTX) when administered with fixed doses of carboplatin, etoposide, and melphalan (CEM) followed by autologous hematopoietic stem-cell transplantation (HSCT) in children with recurrent or high-risk solid tumors as a consolidation chemotherapy, and to make preliminary observations on efficacy. PATIENTS AND METHODS Twenty-seven patients with solid tumors between the ages of 2 and 21 years were enrolled. Twenty of 27 had recurrent disease, whereas seven were treated in first remission. Nine were treated with melphalan 50 mg/m2/d for 4 days, carboplatin 300 mg/m2/d for 4 days as a continuous infusion (CI), and etoposide 200 mg/m2/d for 4 days as a CI (level I). CTX 750 mg/m2/d for 4 days was added to this regimen for the next 18 patients (level II). Seven of nine patients at level I and four of 18 at level II received bone marrow (BM) only, while two of nine at level I and 14 of 18 at level II received BM plus peripheral-blood stem cells (PBSC). RESULTS The median time to reach an absolute neutrophil count (ANC) greater than 500/microl was 12.5 and 10 days for patients who received BM only and BM plus PBSC, respectively. Three cases of grade 3 mucositis, one Candida sepsis, and two transient hypoxemias were the main nonfatal toxicities. No toxic mortality was observed among level I patients. Three of 18 (16%) level II patients, all in second CR, died of transplant-related complications. Median follow-up is 29 months. Nine died of progressive disease (one second malignancy), six relapsed and are alive with disease, and nine are in continuous CR. Among the 15 PNET/Ewing's sarcoma patients, seven are in continuous CR (three of nine in second CR/VGPR, four of six in first CR/VGPR). CONCLUSION The addition of CTX 3 g/m2 to CEM followed by autologous HSCT as a consolidation therapy resulted in 16% toxic mortality in children with recurrent or high-risk solid tumors. Further CTX dose escalation was aborted. No common nonhematologic toxicity was identified. The event-free survival (EFS) of 66% +/- 19% at 3 years for patients with metastatic PNET/Ewing's sarcoma in first remission is encouraging. However, this is based on only six patients. Both level I and II need further exploration in high-risk pediatric solid tumors in first remission." @default.
• W1910228005 created "2016-06-24" @default.
• W1910228005 creator A5001697191 @default.
• W1910228005 creator A5024968001 @default.
• W1910228005 creator A5035076423 @default.
• W1910228005 creator A5035506178 @default.
• W1910228005 creator A5055664953 @default.
• W1910228005 creator A5058354009 @default.
• W1910228005 creator A5059528446 @default.
• W1910228005 creator A5064007701 @default.
• W1910228005 creator A5067145358 @default.
• W1910228005 date "1998-03-01" @default.
• W1910228005 modified "2023-09-27" @default.
• W1910228005 title "Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors." @default.
• W1910228005 cites W1525684755 @default.
• W1910228005 cites W1813712453 @default.
• W1910228005 cites W1831803445 @default.
• W1910228005 cites W1849177728 @default.
• W1910228005 cites W1916635100 @default.
• W1910228005 cites W1920742048 @default.
• W1910228005 cites W1925278504 @default.
• W1910228005 cites W1933116774 @default.
• W1910228005 cites W1934049722 @default.
• W1910228005 cites W1982632015 @default.
• W1910228005 cites W1986645531 @default.
• W1910228005 cites W1987759419 @default.
• W1910228005 cites W1989946391 @default.
• W1910228005 cites W1992622163 @default.
• W1910228005 cites W2010991166 @default.
• W1910228005 cites W2011929591 @default.
• W1910228005 cites W2026810896 @default.
• W1910228005 cites W2040785900 @default.
• W1910228005 cites W2045919099 @default.
• W1910228005 cites W2049208274 @default.
• W1910228005 cites W2062917090 @default.
• W1910228005 cites W2065695389 @default.
• W1910228005 cites W2083765984 @default.
• W1910228005 cites W2102152703 @default.
• W1910228005 cites W2116996913 @default.
• W1910228005 cites W2121896285 @default.
• W1910228005 cites W2168847627 @default.
• W1910228005 cites W2172744800 @default.
• W1910228005 cites W2215118042 @default.
• W1910228005 cites W2227545313 @default.
• W1910228005 cites W2245710266 @default.
• W1910228005 cites W2263842574 @default.
• W1910228005 cites W2333314505 @default.
• W1910228005 cites W2409328022 @default.
• W1910228005 cites W2409817159 @default.
• W1910228005 cites W2417485617 @default.
• W1910228005 cites W2418463498 @default.
• W1910228005 cites W2428832213 @default.
• W1910228005 cites W2431766362 @default.
• W1910228005 cites W2464579757 @default.
• W1910228005 cites W2465100792 @default.
• W1910228005 doi "https://doi.org/10.1200/jco.1998.16.3.937" @default.
• W1910228005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9508176" @default.
• W1910228005 hasPublicationYear "1998" @default.
• W1910228005 type Work @default.
• W1910228005 sameAs 1910228005 @default.
• W1910228005 citedByCount "25" @default.
• W1910228005 countsByYear W19102280052012 @default.
• W1910228005 countsByYear W19102280052013 @default.
• W1910228005 crossrefType "journal-article" @default.
• W1910228005 hasAuthorship W1910228005A5001697191 @default.
• W1910228005 hasAuthorship W1910228005A5024968001 @default.
• W1910228005 hasAuthorship W1910228005A5035076423 @default.
• W1910228005 hasAuthorship W1910228005A5035506178 @default.
• W1910228005 hasAuthorship W1910228005A5055664953 @default.
• W1910228005 hasAuthorship W1910228005A5058354009 @default.
• W1910228005 hasAuthorship W1910228005A5059528446 @default.
• W1910228005 hasAuthorship W1910228005A5064007701 @default.
• W1910228005 hasAuthorship W1910228005A5067145358 @default.
• W1910228005 hasConcept C126322002 @default.
• W1910228005 hasConcept C141071460 @default.
• W1910228005 hasConcept C2776694085 @default.
• W1910228005 hasConcept C2776755627 @default.
• W1910228005 hasConcept C2777063308 @default.
• W1910228005 hasConcept C2777408962 @default.
• W1910228005 hasConcept C2778119113 @default.
• W1910228005 hasConcept C2778239845 @default.
• W1910228005 hasConcept C2778496288 @default.
• W1910228005 hasConcept C2778684742 @default.
• W1910228005 hasConcept C2778880498 @default.
• W1910228005 hasConcept C2781413609 @default.
• W1910228005 hasConcept C2781451048 @default.
• W1910228005 hasConcept C2911091166 @default.
• W1910228005 hasConcept C71924100 @default.
• W1910228005 hasConcept C74133956 @default.
• W1910228005 hasConcept C90924648 @default.
• W1910228005 hasConceptScore W1910228005C126322002 @default.
• W1910228005 hasConceptScore W1910228005C141071460 @default.
• W1910228005 hasConceptScore W1910228005C2776694085 @default.
• W1910228005 hasConceptScore W1910228005C2776755627 @default.
• W1910228005 hasConceptScore W1910228005C2777063308 @default.
• W1910228005 hasConceptScore W1910228005C2777408962 @default.
• W1910228005 hasConceptScore W1910228005C2778119113 @default.
• W1910228005 hasConceptScore W1910228005C2778239845 @default.

• next